Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Fuji
Teva
Fish and Richardson
Johnson and Johnson
Colorcon
US Army
Covington
Mallinckrodt
Medtronic

Generated: February 24, 2018

DrugPatentWatch Database Preview

Claims for Patent: 6,551,616

« Back to Dashboard

Summary for Patent: 6,551,616
Title: Extended release formulations of erythromycin derivatives
Abstract:Disclosed is a pharmaceutical composition for extended release of an erythromycin derivative in the gastrointestinal environment. The composition comprises an erythromycin derivative and a pharmaceutically acceptable polymer so that, when ingested orally, the composition induces statistically significantly lower C.sub.max in the plasma than an immediate release composition of the erythromycin derivative while maintaining bioavailability and minimum concentration substantially equivalent to that of the immediate release composition of the erythromycin derivative upon multiple dosing. The compositions of the invention have an improved taste profile and reduced gastrointestinal side effects as compared to those for the immediate release composition.
Inventor(s): Notario; Gerard F. (Chicago, IL), Palmer; Robert N. (Gurnee, IL), Hom; Richard C. (Wilmette, IL), Zhang; Jie (Basking Ridge, NJ), Devcich; Karen J. (Grayslake, IL), Semla; Susan J. (Evanston, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:09/416,916
Patent Claims: 1. A method of reducing gastrointestinal adverse side effects comprising administering an effective amount of an extended release pharmaceutical composition comprising an erythromycin derivative and a pharmaceutically acceptable polymer.

2. The method according to claim 1, wherein the erythromycin derivative is clarithromycin.

3. The method according to claim 2, wherein the composition comprises about 50% by weight of clarithromycin.

4. The method according to claim 3, wherein the composition comprises from about 10 to about 30% by weight of hydroxypropylmethylcellulose having a viscosity of about 100 cps.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Merck
US Army
Harvard Business School
QuintilesIMS
US Department of Justice
Cipla
Cantor Fitzgerald
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot